Effects of specific immunotherapy along with medication on quality of life in allergic rhinitis patients

authors:

avatar Mohammad Nabavi , avatar Hossein Derakhshani , avatar Saba Arshi , avatar MohammadHasan Bemanian , avatar Morteza Fallahpour , avatar Sima Shokri , * , avatar Raheb Ghorbani ORCID

Koomesh: Vol.19, issue 4; 828-836
published online: May 02, 2017
article type: Research Article
received: October 04, 2016
accepted: May 02, 2017

how to cite: Nabavi M, Derakhshani H, Arshi S, Bemanian M, Fallahpour M, et al. Effects of specific immunotherapy along with medication on quality of life in allergic rhinitis patients. koomesh. 2017;19(4):e152930. 

Abstract

Introduction: Allergen immunotherapy is a novel method for treatment of allergic rhinitis. The purpose of this study is to evaluate the effect of specific immunotherapy on quality of life in patients with allergic rhinitis. Materials and Methods: In this quasi-experimental study, 60 patients with allergic rhinitis, who were above 18 years old and were undergone skin prick test, were included.  30 patients underwent medical treatment plus specific immunotherapy (first group) and also another 30 patients (second group) underwent medical treatment only.  Rhino conjunctivitis quality of life questionnaire was filled out at the beginning, 6 months and 12 months after treatment Results: Among the patients of the first group, 76.7% and among the patients of the second  group, 70% of patients had moderate to severe rhinitis. The two groups were similar according to disease severity (p=0.563). Data revealed that quality of life was not significantly different between two groups before treatment. The mean quality of life scores after 6 and 12 months from the beginning of treatment, were significantly lower in first group (1.11 and 0.31 respectively) compared with the second group (1.89 and 1.89 respectively) (P

References

  • 1.

    Leynaert B, Neukirch C, Liard R, Bousquet J, Neukirch F. Quality of life in allergic rhinitis and asthma: a population-based study of young adults. Am J Respir Crit Care Med 2000; 162: 1391-1396.

  • 2.

    Nabavi M, Ghorbani R, Bemanian M, Rezaie M. Prevalence of mold allergy in patients with allergic rhinitis referred to Semnan clinic of allergy. Koomesh 2009; 11: 27-32.

  • 3.

    Bousquet J, Van Cauwenberge P, Khaltaev N. Allergic rhinitis and its impact on asthma 2010 revision. J Allergy Clin Immunol 2010; 126: 466-476.

  • 4.

    Fell W, Mabry R, Mabry C. Quality of life analysis of patients undergoing immunotherapy for allergic rhinitis. Ear Nose Throat J 1997; 76: 528-532, 34-36.

  • 5.

    Nagaraju K. Manual of Pediatric Allergy: JP Medical Ltd; 2013.

  • 6.

    Camelo-Nunes IC, Sol D. Allergic rhinitis: indicators of quality of life. J Bras Pneumol 2010; 36: 124-133.

  • 7.

    Passalacqua G, Durham SR. Allergic rhinitis and its impact on asthma update: allergen immunotherapy. J Allergy Clin Immunol 2007; 119: 881-891.

  • 8.

    Sheikh A, Platts-Mills T, Worth A, Holgate S. Landmark Papers in Allergy: Seminal Papers in Allergy with Expert Commentaries: Oxford University Press; 2013.

  • 9.

    for Clinical JMEC. Subcutaneous and Sublingual Immunotherapy To Treat Allergic Rhinitis/Rhinoconjunctivitis and Asthma. 2013.

  • 10.

    Meltzer EO. Quality of life in adults and children with allergic rhinitis. J Allergy Clin Immunol 2001; 108: S45-S53.

  • 11.

    Juniper E. Quality of life in adults and children with asthma and rhinitis. Allergy 1997; 52: 971-977.

  • 12.

    Moncayo CC, Rosas VM, del Rio NB, Lerma OL, Velzquez AY, Sienra MJ. [Quality of life in children with allergic rhinitis before and after being treated with specific immunotherapy (cases and controls)]. Rev Alerg Mex 2002; 50: 170-175.

  • 13.

    Zhang L, Wang C, Wang X, Zhao Y, Liu J, Zhang W, et al. [Efficacy and safety of cluster immunotherapy for 154 patients with allergic rhinitis]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2008; 43: 187-191.

  • 14.

    Madiadipoera T, Dahlan A, editors. Improvement of quality of life and daytime sleepiness in Perennial Allergic Rhinitis patients treated with immunotherapy. International Congress Series; 2003: Elsevier.

  • 15.

    Kopp M, Hamelmann E, Zielen S, Kamin W, Bergmann KC, Sieder C, et al. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and comorbid seasonal allergic asthma. Clin Exp Allergy 2009; 39: 271-279.

  • 16.

    Kim SH, Shin SY, Lee KH, Kim SW, Cho JS. Long-term effects of specific allergen immunotherapy against house dust mites in polysensitized patients with allergic rhinitis. Allergy Asthma Immunol Res 2014; 6: 535-540.

  • 17.

    Nelson HS. Multiallergen immunotherapy for allergic rhinitis and asthma. J Allergy Clin Immunol 2009; 123: 763-769.

  • 18.

    Feng S, Xu Y, Ma R, Sun Y, Luo X, Li H. Cluster subcutaneous allergen specific immunotherapy for the treatment of allergic rhinitis: a systematic review and meta-analysis. PloS One 2014; 9: e86529.

  • 19.

    Rhee CS. Current specific immunotherapy for allergic rhinitis: perspectives from otorhinolaryngologists. Allergy Asthma Immunol Res 2014; 6: 273-275.

  • 20.

    Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of allergic rhinitis: an analysis of randomized, prospective, single-or double-blind, placebo-controlled studies. Clin Ther 2000; 22: 342-350.

  • 21.

    Sapsaprang S, Setabutr D, Kulalert P, Temboonnark P, Poachanukoon O, editors. Evaluating the impact of allergic rhinitis on quality of life among Thai students. International forum of allergy & rhinology; 2015: Wiley Online Library.

  • 22.

    DAmato G, G.Rumi E. Cantera M. Cortes, Improvement of quality of life in allergic rhinoconjunctivitis patients using nasal filters, apreliminary study. Eur Ann Allergy Clin Immunol 2013; 45: 167-175.

  • 23.

    Franklin Adkinson N, Bochner BS, Burks W. Middeltons Allergy Principles and Practice, 2014:665.

  • 24.

    Filanowicz M, Szynkiewicz E, Cega B, Bartuzi Z. Analysis of the quality of life of patients with asthma and allergic rhinitis after immunotherapy. Postepy Dermatol Alergol 2016; 33: 134-141.